Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era

Bibliographic Details
Main Authors:	Coates, L, O’Dwyer, J, Meads, D, Emery, P, Conaghan, PG, Helliwell, P
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Similar Items

What should be the primary target of "treat to target" in psoriatic arthritis?
by: Coates, LC, et al.
Published: (2018)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
by: O'Dwyer, J, et al.
Published: (2018)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
by: Coates, L, et al.
Published: (2019)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
by: Coates, L, et al.
Published: (2017)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
by: Coates, L, et al.
Published: (2016)

Current concepts and unmet needs in psoriatic arthritis
by: Mahmood, F, et al.
Published: (2017)

Does treat to target or achieving remission improve radiographic outcome in psa?
by: Coates, L, et al.
Published: (2016)

What should be the primary target of ‘treat to target’ in PsA?
by: Coates, L, et al.
Published: (2018)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
by: P.S. Helliwell
Published: (2011-09-01)

Assessing disease activity in psoriatic arthritis: a literature review
by: Tucker, L, et al.
Published: (2018)

Remission in psoriatic arthritis—where are we now?
by: Coates, L, et al.
Published: (2017)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
by: Mathew, A, et al.
Published: (2016)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
by: Helliwell, P, et al.
Published: (2019)

Novel concepts in psoriatic arthritis management: Can we treat to target?
by: Tucker, L, et al.
Published: (2018)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
by: Coates, L, et al.
Published: (2016)

Sustained very low disease activity and remission in psoriatic arthritis patients
by: Lubrano, E, et al.
Published: (2019)

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review
by: Laura J. Tucker, et al.
Published: (2018-11-01)

Psoriatic Arthritis: A Review
by: Farrouq Mahmood, et al.
Published: (2016-07-01)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
by: Dures, E, et al.
Published: (2020)

2-years outcomes of the treat-to-target strategy in early psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-11-01)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
by: Coates, L, et al.
Published: (2018)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
by: Ennio Lubrano, et al.
Published: (2019-08-01)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
by: Waller J, et al.
Published: (2017-03-01)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
by: Weinstein, SM, et al.
Published: (2021)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
by: Helliwell, P, et al.
Published: (2018)

Psoriatic arthritis: prospects for the future
by: Hackett, S, et al.
Published: (2022)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Dafna D. Gladman, et al.
Published: (2022-02-01)

Implementation of the Treat-to-Target Concept in Evaluation of Psoriatic Arthritis Patients
by: Tal Gazitt, et al.
Published: (2021-11-01)

Psoriatic arthritis: prospects for the future
by: Simon Hackett, et al.
Published: (2022-03-01)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
by: Smolen, JS, et al.
Published: (2017)

The road to personalised medicine in psoriatic arthritis
by: White, JPE, et al.
Published: (2021)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
by: Ye, W, et al.
Published: (2021)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
by: Helliwell, PS, et al.
Published: (2021)

Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel
by: Coates, LC, et al.
Published: (2024)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
by: Helliwell, P, et al.
Published: (2018)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)